Mylan and Biocon Hit With Second CRL for Insulin Glargine Biosimilar

Drug Industry Daily
A A
The FDA has again shot down Mylan and Biocon’s copycat of Sanofi’s Lantus (insulin glargine) with a complete response letter, pending the completion of corrective actions at Biocon’s Malaysian insulin plant.

To View This Article:

Login

Subscribe To Drug Industry Daily